The Blue Book Standards for the Management and Evaluation of STI
Total Page:16
File Type:pdf, Size:1020Kb
GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES The Blue Book Standards GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES for the Management and BACTERIAL VAGINOSIS TRICHOMONIASIS Evaluation of STI Clinic PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV Clients SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS PUBIC LICE HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV SYPHILIS YEAST SCABIES BACTERIAL VAGINOSIS TRICHOMONIASIS Last Revised: June 2021 PUBIC LICE1 HERPES GONORHEA CHLAMYDIA NGU MPC HIV HPV YEAST pSYPHILIS YEAST SCABIES Acknowledgements A committee of provincial sexually transmitted disease representatives convened by Alberta Health Services (AHS) prepared this manual. Thanks are extended to the members of the STI Blue Book Working Group and the staff of the Alberta Provincial Laboratory for Public Health for their expertise and time to provide input and feedback in the development of the document. Special thanks extended to Tammy Troute-Wood and Marni Panas for their expert review of the Caring For the Trans, Non-Binary and Two-Spirit Client chapter. Members of the committee were: Marla Dane (Chair) Clinical Instructor, Calgary STI Clinic, AHS Lindsay Rathjen Director, Provincial STI Programs, AHS Jennifer Gratrix Manager, STI Centralized Services, AHS Logan Chinski Manager, Calgary STI Clinic, AHS Alyshah Lalany (Chair) Clinical Instructor, Edmonton STI Clinic, AHS Dawn Leduc Interim Clinical Instructor, Edmonton STI Clinic, AHS Michelle Fudge STI Clinic RN, Fort McMurray STI Clinic, AHS Diane McKimmie Associate Manager, Fort McMurray STI Clinic, AHS Garret Meyer Manager, Edmonton STI Clinic, AHS Dr. Angel Chu Medical Director, Calgary STI Clinic, AHS Dr. Petra Smyczek Medical Director, Provincial STI Services, AHS Committee Reports to: Christopher Wood Executive Director, Communicable Disease Control, AHS 2 Table of Contents Acknowledgements...................................................................................................... 2 Members of the committee were: ............................................................................................................................ 2 Committee Reports to: .................................................................................................................................................. 2 Summary of Changes (Updates/Revisions) since April 2019 .............................. 11 II Physical Assessment ............................................................................................................................................. 11 D. Specific Examination ............................................................................................................................................ 11 E. Testicular Pain/Swelling – Algorithm ............................................................................................................ 12 Added: Section C. Transgender Males and Females (see section XV Caring for the Trans Client) ................................................................................................................................................................................. 12 A. External Reproductive organs (male) ........................................................................................................... 12 C. Testing ............................................................................................................................................................................. 12 Added: history of 3 documented doses of Hepatitis B immunization. ............................................... 12 G. Lesions ........................................................................................................................................................................ 12 1. Direct testing for Herpes Simplex virus and Syphilis PCR testing ............................................... 12 F. Diagnosis of genital ulcer disease ................................................................................................................... 12 2. Herpes Simplex Virus (HSV) ............................................................................................................................... 12 G. Treatment of Genital Ulcer Disease ............................................................................................................. 13 1. Syphilis ............................................................................................................................................................................. 13 G. Treatment of Genital Ulcer Disease ............................................................................................................. 13 1. Syphilis ............................................................................................................................................................................. 13 C. Testing ............................................................................................................................................................................. 13 2. Screening for Hepatitis B (HBsAb, HBsAg, Anti-HBc) ........................................................................ 13 C. Testing ............................................................................................................................................................................. 13 C. Testing ............................................................................................................................................................................. 14 2. Hepatitis B (HBsAG, HBsAb, Anti-HBc) ....................................................................................................... 14 C. Testing ............................................................................................................................................................................. 14 3. Hepatitis C (Anti-HCV antibody and HCV RNA) ..................................................................................... 14 E. Counselling ................................................................................................................................................................ 14 E. Counselling ................................................................................................................................................................ 14 Notification of Sexually Transmitted Infections (STI) and Treatment ................. 15 Notifiable Disease Management Guidelines ........................................................... 16 Consent ....................................................................................................................... 17 Overview ........................................................................................................................................................................... 17 Most Responsible Health Practitioner ................................................................................................................ 18 Implied Consent ............................................................................................................................................................ 18 Minors / Mature Minors .............................................................................................................................................. 18 Assessment of Mature Minors ............................................................................................................................... 19 Documentation of Assessment ............................................................................................................................. 20 Consent via an Interpreter / Telephone / Fax ................................................................................................ 20 Blood and Blood Products: Consent Policy: ................................................................................................... 20 I. History ...................................................................................................................... 21 A. Chief Complaint ....................................................................................................................................................... 21 B. Functional Inquiry ................................................................................................................................................... 21 1. Male .............................................................................................................................................................................. 21 2. Female......................................................................................................................................................................... 22 3 C. Drug/Other Allergy ................................................................................................................................................